Nabriva Therapeutics appoints Elyse Seltzer as chief medical officer

22 May 2015

Clinical-stage infection-focused biopharma company Nabriva Therapeutics has appointed Elyse Seltzer as chief medical officer.

She will supervise medical and regulatory aspects of clinical development and medical affairs and contribute to Nabriva’s clinical development strategy. She will work closely with Steven Gelone, the recently-appointed chief development officer at Nabriva, as well as the clinical operations team, to execute clinical development including the Phase III trials of lefamulin.

Dr Seltzer joins the company from GlaxoSmithKline (LSE: GSK), where she was vice president of global clinical sciences and operations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK